Cooley-Led Biotech Nixes IPO, Scores $142M Funding Round
Cancer-focused biotechnology firm Poseida Therapeutics Inc. has decided to put plans for an initial public offering on hold, with the Cooley LLP-guided company instead picking up $142 million in a funding...To view the full article, register now.
Already a subscriber? Click here to view full article